Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycerin SCHEMBL3843204 | 0.91 | POLB (0.83) | POLBMAPTSMN1; SMN2HTTP2RX7 | |
| SCHEMBL15082379 | 0.88 | POLB (0.79) | POLBMAPTSMN1; SMN2HTTL3MBTL1 | |
| Triethylene Glycol SCHEMBL1360705 | 0.87 | POLB (0.76) | POLBMAPTSMN1; SMN2HTTP2RX7 | |
| SCHEMBL10039387 | 0.86 | POLB (0.76) | POLBMAPTSMN1; SMN2P2RX7L3MBTL1 | |
| SCHEMBL14477946 | 0.85 | POLB (0.73) | POLBMAPTSMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL2523994 | 0.84 | POLB (0.72) | POLBMAPTSMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL3829535 | 0.82 | POLB (0.67) | POLBMAPTSMN1; SMN2HTTP2RX7 | |
| SCHEMBL15042171 | 0.82 | POLB (0.69) | POLBMAPTP2RX7KMT2AALDH1A1 | |
| SCHEMBL12145251 | 0.81 | POLB (0.68) | POLBMAPTP2RX7L3MBTL1KMT2A | |
| SCHEMBL8293964 | 0.80 | POLB (0.67) | POLBMAPTSMN1; SMN2HTTP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761542-B1 | OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-01-02 | — | — | EP | claimed |
| EP-1761542-A2 | OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | claimed |
| WO-2005121145-A2 | OCTAHYDRO-PYRROLO[3,4-C] DERIVATIVES AND THEIR USE AS ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-22 | — | — | WO | claimed |
| US-8722589-B2 | Use of 1-alkyl-5-oxopyrrolidine-3-carboxylic esters as gas hydrate inhibitors with improved biodegradability | CLARIANT FINANCE (BVI) LIMITED (VG) | 2014-05-13 | — | — | US | disclosed |
| US-8585779-B2 | Composition comprising at least one 2-pyrrolidone functionalized in the 4 position with a carboxylic acid or amide, and at least one direct dye or a pigment for dyeing keratin fibres | L'OREAL (FR) | 2013-11-19 | — | — | US | disclosed |
| US-20130167307-A1 | COMPOSITION COMPRISING AT LEAST ONE 2-PYRROLIDONE FUNCTIONALIZED IN THE 4 POSITION WITH A CARBOXYLIC ACID OR AMIDE, AND AT LEAST ONE DIRECT DYE OR A PIGMENT FOR DYEING KERATIN FIBRES | L'OREAL (FR) | 2013-07-04 | — | — | US | disclosed |
| US-20130167307-A1 | COMPOSITION COMPRISING AT LEAST ONE 2-PYRROLIDONE FUNCTIONALIZED IN THE 4 POSITION WITH A CARBOXYLIC ACID OR AMIDE, AND AT LEAST ONE DIRECT DYE OR A PIGMENT FOR DYEING KERATIN FIBRES | L'OREAL (FR) | 2013-07-04 | — | — | US | disclosed |
| EP-2022781-B1 | 1-Alkyl-5-oxo-pyrrolidine-3-carboxylic acid esters with improved biodegradability | CLARIANT FINANCE BVI LTD (VG) | 2012-02-29 | — | — | EP | disclosed |
| WO-2011154460-A1 | COMPOSITION COMPRISING AT LEAST ONE 2-PYRROLIDONE FUNCTIONALIZED IN THE 4 POSITION WITH A CARBOXYLIC ACID OR AMIDE, AND AT LEAST ONE DIRECT DYE OR A PIGMENT FOR DYEING KERATIN FIBRES | L'OREAL (FR) | 2011-12-15 | — | — | WO | disclosed |
| US-8067651-B2 | 1-alkyl-5-oxopyrrolidine-3-carboxylic esters with improved biodegradability | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-11-29 | — | — | US | disclosed |
| US-7714018-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2010-05-11 | — | — | US | disclosed |
| EP-2028247-A1 | Use of 1-alkyl-5-oxo-pyrrolidine-3-carbolic acid esters as gas hydrate inhibitors with improved biological degradability | CLARIANT INTERNATIONAL LTD. (CH) | 2009-02-25 | — | — | EP | disclosed |
| US-20090043146-A1 | 1-Alkyl-5-oxopyrrolidine-3-carboxylic esters with improved biodegradability | CLARIANT INTERNATIONAL LTD. | 2009-02-12 | — | — | US | disclosed |
| US-20090042747-A1 | Use of 1-alkyl-5-oxopyrrolidine-3-carboxylic esters as gas hydrate inhibitors with improved biodegradability | CLARIANT INTERNATIONAL LTD. | 2009-02-12 | — | — | US | disclosed |
| EP-2022781-A1 | 1-Alkyl-5-oxo-pyrrolidine-3-carboxylic acid esters with improved biodegradability | CLARIANT INTERNATIONAL LTD. (CH) | 2009-02-11 | — | — | EP | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| EP-1761542-B1 | OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-01-02 | — | — | EP | disclosed |
| US-20070117859-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-05-24 | — | — | US | disclosed |
| US-7164019-B2 | Such as cyclopentanecarboxylic acid {(S)-1-phenyl-3-[5-(pyridine-3-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-propyl}-amide; antagonists of chemokine receptors, useful for treating/preventing human immunodeficiency virus infection, AIDS or ARC | ROCHE PALO ALTO LLC (US) | 2007-01-16 | — | — | US | disclosed |
| US-20060014767-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130167307-A1 | COMPOSITION COMPRISING AT LEAST ONE 2-PYRROLIDONE FUNCTIONALIZED IN THE 4 POSITION WITH A CARBOXYLIC ACID OR AMIDE, AND AT LEAST ONE DIRECT DYE OR A PIGMENT FOR DYEING KERATIN FIBRES | KRT18, ADH1A, ADH1C | POLB 648/4885MAPT 205/4885SMN1; SMN2 4384/4885 |
| US-20090043146-A1 | 1-Alkyl-5-oxopyrrolidine-3-carboxylic esters with improved biodegradability | OXER1, CYP1A1, CHRM1 | POLB 952/4885MAPT 3773/4885SMN1; SMN2 3788/4885 |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | SSU72, POLR2H, POLR2E | POLB 79/4885MAPT 3976/4885SMN1; SMN2 4735/4885 |
| US-20060014767-A1 | Heterocyclic antiviral compounds | CCR5, ACKR3, CXCR1 | POLB 2086/4885MAPT 3850/4885SMN1; SMN2 4305/4885 |
| US-20070117859-A1 | Heterocyclic antiviral compounds | CCR5, ACKR3, CXCR1 | POLB 2086/4885MAPT 3850/4885SMN1; SMN2 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.